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Abstract
Introduction: Lipoprotein glomerulopathy is a glomerulonephritis which was described for the
first time by Saito in 1989 and is currently acknowledged as a separate nosological entity. It is
histologically characterized by a marked dilatation of the glomerular capillaries and the presence of
lipoprotein thrombi in the glomerular lumens. The dyslipidemic profile is similar to that of type III
dyslipoproteinemia with Apolipoprotein E values that are often high; proteinuria and renal
dysfunction are present. Proteinuria often does not respond to steroid and cytostatic treatments.
The phenotypic expression of lipoprotein glomerulopathy is most probably correlated to a genetic
alteration of the lipoprotein metabolism (mutation of the Apolipoprotein E coding gene). In
literature, lipoprotein glomerulopathies have mainly been reported in Japanese and Chinese
subjects, except for three cases in the Caucasian race, reported in France and the USA.
Case presentation: We describe the case of a 60-year-old female, Caucasian patient suffering
from lipoprotein glomerulopathy, carrier of a new mutation on the Apolipoprotein E gene
(Apolipoprotein EMODENA), and treated successfully with low density lipoprotein-apheresis with the
Heparin induced extracorporeal lipoprotein precipitation system. After a first phase of therapeutic
protocol with statins, the patient was admitted for nephrotic syndrome, renal failure and
hypertension. Since conventional treatment alone was not able to control dyslipidemia, aphaeretic
treatment with heparin-induced Extracorporeal Lipoprotein Precipitation - apheresis (HELP-
apheresis) was started to maintain angiotensin converting enzyme inhibitor therapy for the
treatment of hypertension. Treatment with HELP-apheresis led to a complete remission of the
proteinuria in a very short time (four months), as well as control of hypercholesterolemia and renal
function recovery.
Conclusion: According to this case of lipoprotein glomerulopathy, we believe that renal damage
expressed by proteinuria correlates to the levels of lipids and, furthermore, the treatment with
HELP-apheresis, by lowering low-density lipoprotein cholesterol and triglycerides, may be
considered as a therapeutic option in synergy with pharmacological treatment in the treatment of
lipoprotein glomerulopathy.
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Introduction
Glomerular damage is frequently caused by fat deposits in
various anomalies of lipid metabolism (Fabry's disease,
Fish Eye disease, von Gierke's disease, type III hyperlipo-
proteinemia), with a glomerulonephritis. This develops
into glomerulosclerosis with severe nephrotic syndrome.
From an initial asymptomatic proteinuria, chronic renal
failure develops gradually as the atherosclerotic process
advances.
The accumulation of lipids in the renal glomerule is a rare
condition, described for the first time by Saito in 1989 [1]
and currently acknowledged as a separate nosological
entity with the term lipoprotein glomerulopathy (LPG).
LPG is histologically characterized by a marked dilatation
of the glomerular capillaries and the presence of thrombi
consisting of fat droplets in the dilated glomerular lumen.
Staining with "Red-O oil" or Sudan red reveals the pres-
ence of these deposits with a "fingerprint" appearance on
ultrastructural analysis. The presence of ApoE and ApoB
can be shown in the thrombi using immunohistochemi-
cal methods. The lipid profile of patients suffering from
this disease is similar to that of type III Hyperlipoproteine-
mia, with high levels of IDL and ApoE. Patients often have
nephrotic proteinuria, but their lipid profile is different
from that of subjects with nephrotic syndrome secondary
to other kinds of glomerulonephritis. While patients with
LPG have high levels of IDL, those with nephrotic syn-
drome due to other causes have high levels of LDL and
VLDL.
The proteinuria in the nephrotic range often does not
respond to steroids and cytostatic treatment.
Many studies attempted to find possible correlations
between plasma levels, polymorphisms, mutations of
ApoE and LPG with contradictory results. The phenotypic
expression of LPG is probably correlated to a mutation of
the coding gene for ApoE.
In the literature, LPGs have mainly been reported in Japa-
nese and Chinese subjects, except for two cases in France
and one in the USA, in Caucasian subjects [2,3].
Case presentation
We describe the case of a 60-year-old Caucasian woman
with a positive familial history for dyslipidemia and
nephropathy.
The patient was first hospitalized in February 2001 with:
hypertension (160/100 mmHg), high lipidic values (cho-
lesterol 372 mg/dl, LDL cholesterol 267 mg/dl, triglycer-
ides 239 mg/dl), creatininemia within the standard limits
(0.9 mg/dl), a corresponding GFR of 63 ml/min calcu-
lated according to Cockroft and Gault, albuminemia of
3.15 gr/dl, total proteins of 5.7 g/dl, and a micro-hematu-
ria, proteinuria (200 mg/dl) and proteinuria and/or albu-
minuria ratio of 2 g/g. The main immunological studies,
ASO, rheumatoid factor, C3-C4, VDRL, serum immuno-
fixation and serum immunoglobulin were normal. The
serum markers for HBV, HCV and HIV were negative. The
leucocyte formula was normal.
A physical examination ruled out the presence of xanthe-
lasma and corneal arc in the absence of edemas. An ultra-
sound revealed kidneys which were regular in dimension
and structure.
A renal biopsy showed the presence of lipid deposits in
the glomerular lumens under the optical microscope after
staining with Red-O oil. The interstitium showed a diffuse
fibrous edema and tubular atrophy in the areas of fibrosis
with a moderate infiltration of inflammatory cells. An
arteriole showed hyaline deposits. An immunofluores-
cence revealed the presence of deposits of IgM and C3 in
the sub endothelial seat. An electronic ultrastructural
analysis confirmed the presence of thrombi in the lumen
of the glomerular capillary loops. The histopathological
diagnosis suspected LPG, but ApoE typing identified the
polymorphism (E2/2) with a diagnosis of familial type III
dyslipoproteinemia.
The patient started treatment with atorvastatin 40 mg/day.
We did not use fibrates in association with statin to avoid
possible side effects. After one year of therapy we observed
a good control of lipid values (cholesterol 250 mg/dl, LDL
cholesterol 114 mg/dl) and a reduction of the proteinuria
(120 mg/dl). Hypertension was controlled (145/90
mmHg) by means of ACE-inhibitors (irbesartan 300 mg/
day, ramipril 5 mg/day), beta-blockers (carvedilole 25
mg/day) and Ca antagonists (nifedipine 60 mg/day).
Four years later in April 2005, the patient was again hos-
pitalized for clinically overt nephrotic syndrome with pro-
teinuria (5 g/24 h) and renal failure (creatinine 2.2 mg/
dl). Arterial hypertension (180/100 mmHg) was hardly
responsive to treatment. The patient had a low response
(cholesterolemia 445 mg/dl, LDL 318 mg/dl, triglycerides
292 mg/dl) to lipid-lowering drugs (atorvastatin 40 mg/
day + cholestyramine 4 g/day + Omega3 fatty acids 2 g/
day) with the presence of periocular thelasmas.
A renal biopsy revealed the presence of lipids with a
fibrous growth of the interstitium and a percentage
increase of sclerotic glomeruli with a diagnosis of LPG
evolved into nephrotic syndrome (histology will be pub-
lished in a manuscript in preparation and when published
the reference will be provided).Journal of Medical Case Reports 2009, 3:9311 http://www.jmedicalcasereports.com/content/3/1/9311
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In view of the patient's poor response to pharmacological
treatment alone, in July 2005 we decided to associate for
the first time in a patient with LPG an LDL-Apheresis pro-
tocol (three aphereses in the first two weeks, then one
weekly session for two months followed by one apheresis
every 15 days) with dextran sulfate columns on the basis
of the evidence present in literature for the treatment of
the steroid-resistant nephrotic syndrome. [4-6]
During the first LDL-apheresis (July 2005) with dextran
sulphate columns (Liposorber System - Kaneka™), an ana-
phylactoid reaction occurred. This complication, as
described by Olbricht in 1992 in patients undergoing
treatment with ACE inhibitors and an LDL-apheresis regi-
men with dextran sulphate columns, is due to the inhibi-
tion of kininases that metabolize bradikynin [7].
To avoid stopping the anti-hypertension treatment with
ACE-inhibitors we decided to use another LDL-apheresis
procedure: the extracorporeal precipitation of LDL-cho-
lesterol induced by heparin in acid pH (HELP System, B.
Braun Avitum™ Melsungen Germany). This procedure
does not involve complications linked to the use of ACE-
inhibitors, following the same protocol previously
described.
The effects of a single HELP-apheresis on vascular home-
ostasis is a simultaneous, drastic reduction within two
hours of cholesterol (-52%), LDL-cholesterol (-56%),
VLDL-cholesterol (-52%), oxLDL (-47%), Lp(a) (-55%),
triglycerides (-50%), fibrinogen (-56%), thrombin (-
55%), von Willebrand factor (-56%), factor V (-57%), fac-
tor VII (-35%), PCR (-56%), plasma viscosity (-14%),
erythrocyte aggregability (-60%), and thrombocyte aggre-
gability (-60%). Also reported in the long-term treatment
was an increase of HDL-cholesterol (+14%), peripheral
muscle oxygenation (+33-50%), coronary flow reserve
(+14%), and cerebral CO2 reactivity (+14%) [8].
In the LDL/fibrinogen apheresis procedure (HELP-apher-
esis), the plasma is obtained by filtration of the whole
blood through a 0.55 μm pore-size filter and then mixed
continuously in a 1:1 ratio with a solution of a 0.2 M
sodium acetate buffer (pH 4.85) containing 100 IU/ml
(300,000 UI) of heparin. The pH of the plasma-buffer
solution reaches 5.12 and, at this value, the heparin binds
the LDL-cholesterol, Lp(a), fibrinogen and triglycerides
forming aggregates. These aggregates precipitate and are
retained by the precipitate filter. Precipitate filter is a 0.4
μm pore-size polycarbonate filter from which plasma free
from LDL-cholesterol, Lp(a) and fibrinogen is obtained
and then passed through an anion exchange filter
(heparin absorber) to adsorb excess heparin. The last stage
of the system (dialysis filter) restores the physiological pH
of the plasma and the balance of the liquids, removing
excess fluid by ultrafiltration. The liquid used for dialysis
is a sterile solution with a bicarbonate concentration of 35
mmol/l. After the dialysis process, the plasma, purified of
lipids and fibrinogen, is returned to the patient mixed
with the haematic cell components.
We processed 3000 ml of plasma. That means about 1.4
patient plasma volumes in two hours, with HELP
machine (Plasmat Futura®, B. Braun Avitum, Melsungen
Germany) and a disposable kit. There were no side effects
with the HELP. method, except that the patient had prob-
lematic vascular accesses leading to flow problems, So, it
became necessary to modify some software parameters
(most notably the "PA minimum" threshold; software
version 2.06.01) to be able to use a 17G fistula needle for
the blood withdrawal and a 20G cannula needle for the
blood reinfusion during the procedure. With this configu-
ration, the flows were relatively moderate for an LDL-
apheresis (blood flow of 50 ml/min and plasma flow of
20 ml/min), to complete the treatment target of 3000 ml.
After some procedures we proceeded with the use of an
18G fistula needle in re-entry, maintaining a 17G fistula
needle for drawing, obtaining flows that were definitely
higher (blood flow of 80-100 ml/min and plasma flows of
25-30 ml/min). By increasing the flows, there was a
marked reduction in the duration of the individual proce-
dure, super-imposable to that of a patient with good vas-
cular accesses.
After two months of treatment with LDL-apheresis (10
procedures), the laboratory data showed a progressive
increase of albuminemia (from 3.39 to 3.70 g/dl) with
partial remission of proteinuria (from 3.3 to 2 expressed
as urine protein to creatinine ratio. A ratio of 0.1 is normal
- protein and creatinine are expressed in mg/dl); and a
progressive decline in creatininemia (from 1.9 to 1.6 mg/
dl). The patient's anemia was improving and her arterial
pressure was well under control with a reduction of the
pharmacological dose, compared to two months earlier.
There was also a significant drop in the mean values of TG
(from 285 to 231 mg/dl) and LDL-Cholesterol (from 178
to 158 mg/dl) with reduction of xanthelasma. Pre-apher-
esis fibrinogen and Lp(a) mean values did not show a sig-
nificant reduction. Considering the patient's clinical
condition improvement, we decided to reduce the statins
dosage (from 40 to 20 mg/die) continuing LDL-apheresis
protocol of one session every two weeks.
Four months after aphaeretic treatment (15 procedures),
the patient's albuminemia values were maintained (3.70
g/dl), her creatinine (1.3 mg/dl) and proteinuria (ratio
1.3) were reduced and her arterial pressure was stabilized
(120-80 mmHg). There was a further reduction of LDL-
cholesterol (105 mg/dl) and TG (134 mg/dl) mean val-
ues, with a suspension of cholestyramine and Omega-3Journal of Medical Case Reports 2009, 3:9311 http://www.jmedicalcasereports.com/content/3/1/9311
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fatty acids treatment and a further reduction of the xan-
thelasmas. The LDL-Apheresis session was reduced to one
session every three weeks.
After ten months (25 procedures) the laboratory data were
as follows: creatinine 1.6 mg/dl, albuminemia 4.30 g/dl,
proteinuria (ratio 0.13), LDL-cholesterol 106 mg/dl and
TG 154 mg/dl. The values of Lp(a) and fibrinogen are
unchanged (Figure 1, 2).
After two years of follow up, with a maintenance treat-
ment of one LDL-apheresis session every three weeks in
the last period, the mean biochemical values were: choles-
terol 199 mg/dl, LDL-cholesterol 110 mg/dl, HDL-choles-
terol 76 mg/dl, TG 112 mg/dl, fibrinogen 381 mg/dl,
creatininemia 1.5 mg/dl, Proteinuria ratio 0.9, arterial
pressure 120-80 mmHg. The pharmacological therapy is
unchanged.
The sequence of the ApoE gene made in 2007 showed that
the patient was homozygous for epsilon-2 allele (poly-
morphism E2/2 with Cys112 and Cys158 in the mature
protein) and heterozygous for a novel mutation in exon 4:
c.502 C>T [Arg 150>Cys of mature protein]. The mutant
Apo E (ApoEMODENA) expresses a new residue of Cys in
place of an Arg. This new cysteine residue could form a
disulphide bridge with the other Cys residue of the E2 iso-
form resulting in ApoE polymerization (dominant nega-
tive effect). This phenomenon is probably the cause of
both dyslipidemia and lipid thrombi in the glomerular
capillaries [9].
Discussion
The limitations of this case report are due to its rarity (as far
as we know it is the first case of LPG in Italy) as well as the
difficulty to reach the diagnosis (the sequence of the ApoE
gene in 2007 made it possible for a complete diagnosis of
LPG to be confirmed). In July 2005, after the poor response
of the patient to lipid-lowering drugs, we decided to start
with an LDL-Apheresis protocol as possible treatment
instead of ApoE and TG to stop the glomerular damage. In
patients with familial hypercholesterolemia, kidneys are
Lipids and Fibrinogen values before every single H.E.L.P.-apheresis (first ten months of treatment) Figure 1
Lipids and Fibrinogen values before every single H.E.L.P.-apheresis (first ten months of treatment). After the 
first ten months of apheretic treatment the mean values were: Total Cholesterol from 243 mg/dl to 184 mg/dl, HDL-Choles-
terol from 65 mg/dl to 77 mg/dl, LDL-Cholesterol from 178 mg/dl to 106 mg/dl, Triglycerides from 285 mg/dl to 161 mg/dl, 
Fibrinogen from 405 mg/dl to 378 mg/dl, Lp(a) from 61 mg/dl to 51 mg/dl.
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frequently damaged by fat deposits leading to glomeru-
lonephritis which develops into glomerulosclerosis with
severe nephrotic syndrome. The direct negative effects of
lipids and pro-inflammatory markers on the renal arteries
endothelium are due to the formation of free radicals
because of oxidized LDL (oxLDL). This induces an inflam-
matory condition with an impairment of the endothelial
function. There is glomerular damage and passive filtration
of lipoproteins in the mesangium with active phagocytosis
by a part of the mesangial cells and macrophages which, by
releasing cytokines and growth factors, increase mesangial
proliferation [10]. In patients refractory to conventional
treatment (diet and statins), LDL-apheresis is a valid thera-
peutic tool to be associated with drugs to rapidly reduce the
hematic lipid values [11] and improve renal function,
thereby reducing the toxic effect [12].
LDL apheresis has been used in the treatment of steroid-
resistant nephrotic syndromes [13,14]. It has been used to
reduce the inflammatory condition linked to the produc-
tion of cytokine (IL-8) by the macrophages activated and
by the abnormal numbers of oxLDL [15]. In addition, it
has also been used to improve renal hemodynamics by
reducing the production of vasoconstrictor eicosanoids
(Thromboxane A2) and increasing Prostaglandin I2. LDL
apheresis has also been used to increase the response to
steroid therapy by removing the VLDL, which induces a
reduction of dose-dependent specific binding sites for the
dexamethasone on smooth muscle cells [16].
A potential advantage of HELP-apheresis versus dextran
sulfate columns in the treatment of LPG may be related to
the use of high heparin dosages. Heparin may activate LPL
and HTGL and easily remove lipoproteins rich of TG like
VLDL and IDL that are generally elevated in LPG. Another
potential advantage of HELP-apheresis versus dextran sul-
fate may be the dialysis circuit present in the HELP-Plas-
mat Futura machine. This plasmatic dialysis process,
fundamental to restoring the plasmatic physiological pH
and the balance of fluid, is also able to slightly correct
impaired renal parameters such as creatinine, urea, and
uric acid, as reported by Thiery [17]. Furthermore, a strong
improvement of hemorheology (viscosity reduction),
thanks to the simultaneous removal of lipids (LDL, VLDL,
Creatinine and Urine Protein to Creatinine Ratio before every H.E.L.P.-apheresis (first ten months of treatment) Figure 2
Creatinine and Urine Protein to Creatinine Ratio before every H.E.L.P.-apheresis (first ten months of treat-
ment). After the first ten months of apheretic treatment the mean values were: Creatinine from 1.9 mg/dl to 1.5 mg/dl and 
Urine Protein to Creatinine Ratio from 3.3 to 0.13 (protein and creatinine are expressed in mg/dl).
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Lp(a), triglycerides), associated with the removal of coag-
ulation factors (Fibrinogen, Factor V, Factor VIII, Wille-
brand Factor) and pro-inflammatory markers (PCR,
endothelial adhesion molecules) may be obtained by
HELP-apheresis [18,19].
Conclusion
The experience in this case of LPG leads us to believe that
the renal damage expressed by proteinuria correlates with
the levels of lipids. The selective removal of LDL-choles-
terol, Lp(a), TG and fibrinogen through HELP-apheresis
and pharmacological treatment led to the clinical remis-
sion of proteinuria, thereby improving the renal function
parameters (creatininemia and albuminemia). This clini-
cal improvement may be also explained by considering
the capability of the HELP dialysis circuit to correct
impaired renal parameters. This specific tool probably
makes HELP-apheresis a first choice apheretic treatment
for drugs-resistant LPG or nephrotic syndrome. HELP-
apheresis allowed the patient to maintain the use of the
ACE-inhibitor and to reduce the administration of statins
at a lower dosage.
Finally, HELP-apheresis may be considered a therapeutic
option in synergy with pharmacological therapy in the
treatment of LPG.
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